StudyFinder

A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors

Recruiting
I'm interested

18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent malignant tumor. Eligible tumor types are non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction, castration-resistant prostate cancer (CRPC), ovarian, squamous cell carcinoma of the head and neck (SCCHN), bladder, melanoma, mesothelioma, triple negative breast cancer (TNBC), and soft tissue sarcoma, except for participants with tumors with central nervous system (CNS) metastases as the only site of active disease
• Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), Prostate Cancer Working Group 3 (PCWG3) (for prostate cancer), or modified Response Evaluation Criteria in Solid tumors (mRECIST) (for mesothelioma)
• Eastern Cooperative Oncology Group Performance Status of 0 or 1
• Adequate organ function
Exclusion Criteria:

• Prior organ or tissue allograft
• Leptomeningeal metastases
• Untreated CNS metastases
• Serious or uncontrolled medical disorders Other protocol-defined inclusion/exclusion criteria apply

Biological: BMS-986406, Biological: Nivolumab

Advanced Cancer

Opdivo®, Immunotherapy

BMS Study Connect Contact Center www.BMSStudyConnect.com - Clinical.Trials@bms.com
Phase 1
NCT05298592
See this study on ClinicalTrials.gov

Back